Relmada Therapeutics Inc (RLMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 2,086 | 1,335 | 4,092 | 6,699 | 14,469 |
| Marketable Securities | 68,351 | 82,278 | 92,232 | 99,569 | 104,060 |
| TOTAL | $70,975 | $84,365 | $97,509 | $109,101 | $122,004 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 54 | 43 | 43 | 48 | 35 |
| TOTAL | $54 | $43 | $43 | $48 | $35 |
| Total Assets | $71,029 | $84,408 | $97,552 | $109,149 | $122,038 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 4,175 | 5,189 | 3,506 | 2,857 | 4,854 |
| Accrued Expenses | 5,362 | 7,173 | 8,689 | 5,566 | 5,849 |
| TOTAL | $9,537 | $12,362 | $12,195 | $8,422 | $10,703 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $9,537 | $12,362 | $12,195 | $8,422 | $10,703 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 30,174 | 30,174 | 30,174 | 30,099 | 30,099 |
| Common Shares | 30 | 30 | 30 | 30 | 30 |
| Retained earnings | -600,499 | -582,731 | -560,903 | -535,738 | -513,736 |
| TOTAL | $61,492 | $72,046 | $85,357 | $100,727 | $111,336 |
| Total Liabilities And Equity | $71,028 | $84,408 | $97,552 | $109,149 | $122,038 |